DNA X, Inc. reported its full‑year 2025 financial results, noting a net loss for the year and the absence of revenue from continuing operations in the fourth quarter. The loss reflects the company’s ongoing transition away from its legacy mobile‑device business toward a new cryptocurrency trading platform.
The company completed the sale of its mobile‑device design and manufacturing business to NEXA Mobility on January 23 2026. The transaction was valued at $15 million, with $13.5 million paid immediately and $1.5 million deferred. Proceeds were used to repay debt and fund the new trading platform.
In December 2025, DNA X acquired the DNA X cryptocurrency trading platform business for $15 million, again paying $13.5 million upfront and deferring $1.5 million for nine months. This acquisition marks a strategic pivot from hardware to the high‑growth digital‑asset market.
Leadership changes followed the transition. Former CEO Clay Crolius resigned on January 30 2026, and Executive Chairman Mike Mulica was appointed acting CEO effective February 9 2026—a week after the resignation, reflecting a brief interim period.
The company’s independent auditor issued a going‑concern opinion, citing substantial doubt about its ability to continue without additional funding. Management emphasized that the company is in a monitoring and testing phase for the new trading platform and expects future growth as it moves beyond the initial launch.
DNA X’s rebranding from Sonim Technologies to DNA X on January 27 2026 and the transition of its ticker symbol from SONM to DNAX are part of the broader shift. The financials show a significant loss for the year, but the strategic focus on cryptocurrency trading positions the company for potential upside if the market matures.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.